Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 09, 2025, titled "Glenmark Pharmaceuticals to Launch DCGI-approved BRUKINSA? in India to Advance Treatment of Hematological Malignancies".
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals announced it will launch BRUKINSA® (zanubrutinib) in India following approval from the Drug Controller General of India (DCGI). BRUKINSA is the first and only BTK inhibitor approved in India, covering five B-cell blood cancers — chronic lymphocytic leukemia, Waldenström macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, and follicular lymphoma. The drug was originally developed by BeiGene (now BeOne Medicines), and Glenmark is launching it under a partnership. Globally, BRUKINSA is approved in over 70 countries and has been used to treat more than 100,000 patients. The launch targets India's significant blood cancer burden, with roughly 70,000 deaths annually. Clinical trials showed BRUKINSA had fewer serious cardiac side effects compared with ibrutinib (1.9% vs 7.7%).
This is a positive development for Glenmark as it strengthens its oncology portfolio in India and brings an innovative, globally validated cancer therapy to a large underserved market. The partnership with BeiGene/BeOne adds credibility and could support revenue growth in the high-margin specialty oncology segment.